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Late-stage colorectal cancer (CRC) is still a clinically challenging problem.
The activity of the tumor suppressor p53 is regulated via post-translational
modifications (PTMs). While the relevance of p53 C-terminal acetylation
for transcriptional regulation is well defined, it is unknown whether this
PTM controls mitochondrially mediated apoptosis directly. We used wild-
type p53 or p53-negative human CRC cells, cells with acetylation-defective
p53, transformation assays, CRC organoids, and xenograft mouse models
to assess how p53 acetylation determines cellular stress responses. The
topoisomerase-1 inhibitor irinotecan induces acetylation of several lysine
residues within p53. Inhibition of histone deacetylases (HDACs) with the
class I HDAC inhibitor entinostat synergistically triggers mitochondrial
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damage and apoptosis in irinotecan-treated p53-positive CRC cells. This
specifically relies on the C-terminal acetylation of p53 by CREB-binding
protein/p300 and the presence of C-terminally acetylated p53 in complex
with the proapoptotic BCL2 antagonist/killer protein. This control of C-
terminal acetylation by HDACs can mechanistically explain why combina-
tions of irinotecan and entinostat represent clinically tractable agents for
the therapy of p53-proficient CRC.
1. Introduction
Post-translational modifications (PTMs) control major
protein functions and activities. Lysine acetylation of
proteins was discovered more than 50 years ago, and
recent evidence shows that it is one of the most impor-
tant PTMs in vivo [1]. Histone deacetylases (HDACs)
remove acetyl groups from proteins and are divided
into four phylogenetic classes in mammals. Eleven
zinc-dependent enzymes form classes I, II, and IV, and
seven NAD-dependent sirtuins are class III [1]. It has
become clear that HDAC inhibitors (HDACi) will
only develop their therapeutic potential in combination
treatments [2,3].
Colorectal cancer (CRC) is the second most com-
mon cause of cancer death. Alone in the United States,
approximately 147 950 individuals will be diagnosed
with CRC and 53 200 will die from the disease in 2020
[4]. Thus, improved therapies should be identified for
this unmet clinical need. Due to aberrant HDAC activ-
ities in such tumors, HDACi are tested against cancer,
including CRC. All clinically relevant inhibitors block
class I HDACs [5–7]. From a therapeutic perspective,
it is promising that HDACi sensitize tumor cells to
chemotherapeutics causing replication stress (RS) and
DNA damage [8–10]. There is an ongoing intense
search for reliable markers and molecular mechanisms
that indicate whether a cell is responsive to such treat-
ment.
The tumor suppressor p53 modulates the expression
of genes for cell cycle arrest, DNA repair, and apopto-
sis. This allows p53 to control cell fate upon disturbed
DNA replication and damage. Cell cycle arrest and
DNA repair prevail until irreparable or continuous
damage drives the accumulation of proapoptotic p53
target genes [11–13]. Two main pathways initiate
apoptosis. The intrinsic pathway is activated by mito-
chondrial membrane permeabilization (MOMP), and
the extrinsic pathway is triggered by receptor signaling
[14]. Multiple PTMs, including phosphorylation by
checkpoint kinases and acetylation by histone
acetyltransferases (HATs), regulate p53 and increase
the transcription of proapoptotic proteins [13–17].
The relative contributions of an imbalanced pro- and
antiapoptotic BCL2 protein expression and of p53
hyperacetylation by HDACi toward tumor cell apop-
tosis are not fully deciphered [13,17,18]. Regarding
the interactions of p53 with BCL2 proteins, it is
known that the acetylation of the p53 DNA-binding
domain (DBD), which lies in the middle of the pro-
tein, promotes interactions with the proapoptotic
pore-forming proteins BCL2-associated X protein
(BAX) and BCL2 antagonist/killer (BAK) [15–
17,19,20]. However, despite the well-known relevance
of p53 C-terminal acetylation for gene regulation, it
is unclear whether this acetylation of p53 can regulate
MOMP.
Here, we provide new insights into how p53, class I
HDACs, and CREB-binding protein (CBP)/p300 act
as key gatekeepers for the survival of cells with RS.
We used wild-type p53-positive (HCT116wt) and p53-
negative (HCT116δp53) human CRC cell lines, human
primary short-term CRC cell cultures, and patient-
derived CRC organoids to measure cellular responses
to the topoisomerase I (TOP1) inhibitor irinotecan in
combination with the class I HDACi entinostat (MS-
275) and the CBP/p300 inhibitor CPI-1612. Irinotecan
is an FDA-approved drug to treat CRC. It causes tor-
sional DNA damage and RS in S phase and stalls cells
in G2 phase. DNA strand breaks upon prolonged
TOP1 inhibition are repaired by homologous recombi-
nation (HR). Unfortunately, irinotecan frequently pro-
duces severe side effects that lead to a discontinuation
of its use in patients with cancer. Combined treatment
approaches could allow a reduction in the irinotecan
doses that are applied to patients [21–23]. The well-tol-
erated epigenetic drug entinostat is tested in phase III
clinical trials for the treatment of various tumor enti-
ties [6,18]. CPI-1612 is a new inhibitor of CBP and
p300 [24]. We show that the combined application of
irinotecan and entinostat synergistically kills CRC cells
in vitro and in vivo and that the induction of
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HCT116 cells were a gift from B. Vogelstein (Balti-
more, USA). H1299 cells with inducible p53wt or
p53K120R were kindly provided by S. B. McMahon
(Philadelphia, USA) [25]. RKO ATCC cells were
from the DSMZ Braunschweig and a gift from M.
Zörnig (Frankfurt/Main, Germany). DNA finger-
printing analysis using eight different, highly poly-
morphic short tandem repeat loci confirmed cell
authenticity (conducted by the Leibniz Institute
DSMZ, Braunschweig, Germany). Samples were
tested negative for mitochondrial DNA from rodent
cells (mouse, rat, hamster). Cells were maintained in
high glucose (4.5 gL−1) DMEM with stable glu-
tamine, 10% fetal calf serum (FCS), and 250 µgmL−1
gentamycin (Thermo Fisher Scientific, Waltham, MA,
USA). HROC/HHC (Hansestadt Rostock/Hansestadt
Hamburg colon cancer) cells were isolated from
excised CRCs according to Ref. [26]. Low-passaged
cell lines were maintained in DMEM containing 10%
FCS (Pan Biotech, Aidenbach, Germany). A. Poth
(Roßdorf, Germany) kindly provided BALB/c-3T3-
A31-1-1 cells from Hatano Research Institute of
Japan. These were maintained in DMEM/HAM’s F-
12 (3.0 gL−1 glucose; Biochrom, Berlin, Germany),
5% FCS, and 100 UmL−1 penicillin/streptomycin.
Cells between passages 20–40 were used for the
BALB transformation assay (~ 70% confluence). All
cells were cultivated in a humidified incubator at
37 °C with 5% CO2.
2.2. Reagents
Irinotecan hydrochloride (CPT-11) and propidium
iodide (PI) were purchased from Sigma-Aldrich
(Deisenhofen, Germany). Entinostat (MS-275), navito-
clax (ABT-263), and z-VAD-FMK (zVAD) were pur-
chased from Selleck Chemicals (Houston, TX, USA).
3,30-dihexyloxacarbocyanine iodide (DiOC6(3)) was
purchased from Thermo Fisher Scientific. CPI-1612
[24] was kindly provided from M. Trojer (Constella-
tion Pharmaceuticals, Cambridge, MA, USA). DMSO
was used as treatment control.
All other chemicals were bought from Carl Roth
GmbH & Co KG (Karlsruhe, Germany). All buffers
and solutions were prepared with double-distilled
water (ddH2O).
2.3. Treatment of cells
Cells were treated with 1–10 µM irinotecan, 1–2 µM
entinostat, 20 µM zVAD, 500 nM ABT-263, 25–
1000 nM CPI-1612, and their combinations for up to
48 h. If indicated, cells were irradiated with 2 Gy using
137Cs γ-irradiation source (Gammacell 40, Nordion,
Ottawa, ON, Canada).
2.4. Transfection of cells
Cells were transfected with 1 µg of empty vector (EV,
pcDNA3.1), p53wt (pRK5-Flag), and p536KR (pRK5-
Flag) plasmids using 3 µL Lipofectamine 2000 (in
Opti-MEM; Thermo Scientific) per well. p53wt and
p536KR plasmids were kindly provided by W.-G. Zhu
(Shenzen, China). To obtain p53-negative cells with a
reconstitution of p53 isoforms, the cells were trans-
fected using 3 µL Lipofectamine 2000, 1 µg DNA and
0.1 µg of a nontargeted shRNA (pSUPER) (in Opti-
MEM; Thermo Scientific) per well. The empty shRNA
vector contains a puromycin-resistance cassette that
allowed the selection of transfected clones. On the next
day, the medium was changed and 0.1 µgmL−1 puro-
mycin (Invivogen, San Diego, CA, USA) was added.
Every 2–3 days, the puromycin-containing medium
was changed. After 2 weeks of selection, cells were sep-
arated for the first time and the puromycin concentra-
tion was increased to 1 µgmL−1. After another
2 weeks, cells were grown in T25 cell culture flasks
and DMEM containing 1 µgmL−1 puromycin. After
6 weeks of selection, cells stably kept p53 expression in
DMEM without puromycin. Transfection efficiency
and persistence of the reconstitution with p53 were
controlled via immunoblot.
2.5. Human organoid culture
Human intestinal crypts from either tumor tissue or
adjacent healthy tissue were isolated and cultured as
described in Ref. [27] and seeded (100 organoids/well)
in Labtec (Eschelbronn, Germany) chamber slides con-
taining 20 μL of matrigel matrix and 300 μL of growth
medium. Both healthy and tumor organoids were
sequenced, the tumor organoids harbor mutations in
the following genes: ARID1A, PIK3CA, APC, KRAS,
and AMER1, but are wild-type for TP53. The human
organoid study has been approved by the Jena Univer-
sity Hospital Ethics Committee (#5032-01/17).
After 24 h of initial growth, organoids were treated
with irinotecan–entinostat combinations for an
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additional 24 h. Organoid images were captured using
a Zeiss AxioVert 40 CFL microscope and an AxioCam
MRc 5 (Carl Zeiss, Oberkochen, Germany); live and
dead organoids were counted according to their mor-
phological appearance.
2.6. In vivo experiments
Animals used in these experiments were 6- to 8-week-
old male or female NMRI-Foxn1nu mice (16–25 g
body weight). The breeding was done in the animal
facility of the Rostock University Medical Center
under specified pathogen-free conditions. Standard pel-
let food and water ad libitum were given during exposi-
tion to 12-h light/12-h darkness cycles. The tumor
specimens (3 × 3 × 3 mm) were incubated in matrigel
(Corning, Kaiserslautern, Germany) for > 10min at
4 °C prior to flank implantation under anesthesia (ke-
tamine/xylazine, 90/6 mgkg−1 body weight). Therapy
was initiated upon tumor establishment (4–5 mm
diameter). All mouse experiments were performed
according to the guidelines of the local animal use and
care committee (Landesamt für Landwirtschaft,
Lebensmittelsicherheit und Fischerei Mecklenburg-
Vorpommern, permit number: LALLF M-V/TSD/
7221.3-1-063/18).
The mice were randomized into two different ther-
apy groups: (a) control [100 µL 5% DMSO (Appli-
Chem GmbH, Darmstadt, Germany) in 0.9% NaCl
(B. Braun Melsungen AG, Melsungen, Germany),
intraperitoneal (i.p.), thrice weekly, six times in total];
and (b) combination of entinostat (2.5 mgkg−1 bw in
5% DMSO in 0.9% NaCl, orally, five times weekly,
15 times in total) and irinotecan (20 mgkg−1 bw in
5% DMSO in 0.9% NaCl in 100 µL total volume,
i.p., thrice weekly, nine times in total). Tumor
growth and animal behavior were monitored daily.
Animals were sacrificed after therapy completion,
and tumors and livers were resected, weighed, and
photographed.
2.7. Flow cytometric analysis of apoptosis, cell
death, and mitochondrial transmembrane
potential (ΔΨM)
These analyses were performed as previously described
in Ref. [28].
2.8. β-Galactosidase staining
Cellular senescence was measured using the senescence
β-galactosidase staining kit (Cell Signaling Technolo-
gies, Danvers, MS, USA) following the manufacturer’s
instruction. Images were examined using a Zeiss Axio-
Vert 40 CFL microscope and an AxioCam MRc 5
(Carl Zeiss).
2.9. Whole cell lysates and
coimmunoprecipitations
Cell lysates were prepared as described in Ref. [29].
Protein quantification was done by BCA assay
(Thermo Scientific). Coimmunoprecipitation was done
as described in Ref. [30] using 1 µg of anti-BAK or
anti-BCL-XL (Cell Signaling) primary antibodies and
rabbit-IgG (Abcam, Cambridge, UK) as negative con-
trols. Veriblot HRP-coupled secondary antibodies
(Abcam) were used to reveal the proteins.
2.10. Mitochondrial isolation and fractionation of
mitochondria using carbonate treatment
After harvesting by scraping, cells were resuspended in
homogenization buffer [10 mM Tris/HCl (pH 6.7),
10 mM KCl, 150 mM MgCl2] and incubated 10 min on
ice. Cells were homogenized on ice, and sucrose was
added to the suspension (final concentration 0.25 M).
Cellular membrane fragments and nuclei were removed
by two centrifugation steps at 1000 g. Mitochondria
were pelleted at 13 000 g for 10 min afterward. The
supernatant (cytosolic fraction) was removed, and
mitochondria were resuspended in homogenization
buffer and briefly sonicated or used for further frac-
tionation.
Mitochondrial subfractionation was performed as
described in Ref. [31]. Isolated mitochondria were
diluted 50-fold with 100 mM sodium carbonate pH
11.5 and incubated on ice for 30 min. The suspension
was centrifuged at 4 °C for 15 min at 20 000 g. After
removing the supernatant, containing soluble mito-
chondrial matrix proteins, the membrane pellet was
resolved in homogenization buffer (see above). The pH
of the solutions was adjusted to 7 using 1 M HCl after-
ward.
2.11. Immunoblotting
Sample preparation was done as described in Ref. [29].
Antibodies used (Table 1):
Equal loading of protein was verified by the detec-
tion of α-tubulin (1 : 10 000; Sigma-Aldrich), HSP90
(1 : 10 000), TOM40 (1 : 10 000), β-actin (1 : 2000),
vinculin (1 : 5000) (from Santa Cruz Biotechnology
Inc.), or ATP5A (1 : 5000; Abcam). Densitometric
quantification was done with IMAGEJ (National Insti-
tutes of Health, Bethesda, MD, USA).
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2.12. Quantitative real-time PCR
Total RNA was isolated using the Peqgold Total
RNA Kit including DNase digestion (Peqlab, Erlan-
gen, Germany). RNA was transcribed into cDNA
using Omniscript (Qiagen, Hilden, Germany). Quanti-
tative PCR for BBC3, CDKN1A, HDM2, BAX, BIM,
RAD51, TP53I3, BRCA1, BRCA2, FANCD2, BCL2,
BCL2L1, BAK1, BID, 18S, and B2M was performed
using the Applied Biosystems 7900HT Real-Time PCR
system (Darmstadt, Germany). Expression levels were
normalized to β2-microglobulin or 18S rRNA. Reac-
tions were done in duplicate using Applied Biosystems
Gene Expression Assays [BBC3 (PUMA):
Hs00248075_m1, CDKN1A (p21): Hs00355782_m1,
HDM2: Hs99999008_m1, BAX: Hs00180269_m1,
TP53I3 (PIG-3): HS00936520_m1, BCL2L11 (BIM):
Hs00708019_s1, RAD51: Hs00947967_m1, BRCA1:
Hs01556193_m1, BRCA2: Hs00609073_m1, FANCD2:
Hs00276992_m1, BCL2: Hs00608023_m1, BCL2L1
(BCL-XL): Hs00236329_m1, BAK1: Hs 00832876_m1,
BID: Hs00609632_m1, 18S (18S rRNA): Hs99999901_s1,
B2M (β-2-microglobulin): Hs00187842_m1], and Univer-
sal PCR Master Mix. All procedures were performed
according to the manufacturers’ protocols. The rela-
tive gene expressions were calculated by the 2ðΔΔCtÞ
method.
2.13. BALB/c cell transformation assay
This assay was performed as described in Ref. [32].
2.14. Fluorescence microscopy
Cells were fixed with 4% paraformaldehyde (in PBS;
Carl Roth) and incubated in blocking solution (BS:
1% BSA, 0.4% Triton X-100 in PBS). Following, sam-
ples were incubated in primary antibody solutions
against H2AX phosphorylated at serine-139 (γH2AX;
1 : 1000 in BS; Merck Millipore), 53BP1 (1 : 500 in
BS; Novus Biologicals), or RAD51 (1 : 250 in BS;
Santa Cruz), washed in PBS and incubated in Alexa-
Fluor 555-conjugated anti-rabbit (1 : 500 in BS;
Abcam) or AlexaFluor 647-conjugated anti-mouse
(1 : 500 in BS; Thermo Fisher) secondary antibody
solutions. Afterward, samples were stained with
1 µgmL−1 DAPI (Sigma-Aldrich) and mounted with
ProLong Gold Antifade Mountant (Thermo Scientific).
Images were examined using a Zeiss AxioImager Apo-
Tome microscope (structured illumination) (Carl
Zeiss). ZEN 2.0 lite software (Carl Zeiss) was used for
image analysis.
2.15. Transmission electron microscopy
Cells were fixed with 2.5% glutaraldehyde in cacody-
late buffer (0.1 M, pH 7.4), washed with cacodylate
buffer, carefully harvested by scraping, and fixed
within osmium tetroxide (1% in cacodylate buffer).
During ascending ethanol series, samples were stained
with 2% uranyl acetate. The samples were embedded
in Araldite resin (Plano, Wetzlar, Germany) according
to the manufacturer’s instruction. Ultrathin sections of
50 nm thickness were cut using an Ultracut E ultrami-
crotome (Reichert–Jung, Wien, Austria) and mounted
on Formvar/Carbon coated grids (100 Mesh, Quan-
tifoil Micro Tools GmbH, Jena, Germany). Finally,
Table 1. List of primary antibodies used in this study.
Antigen Dilution Company
p53 (DO-1) 1 : 5000 Santa Cruz Biotechnology Inc.,
Heidelberg, GermanyMDM2 1 : 1000
BAX 1 : 1000
RAD51 1 : 1000
p16 1 : 2500
p19 1 : 1000
BRCA1 1 : 100
Cyclin B1 1 : 1000
Cytochrome c 1 : 2500










RPA32 1 : 2500
Phospho-serine 10
histone H3
1 : 2500 Merck Millipore, Darmstadt,
Germany
Acetyl-histone H3 1 : 5000




1 : 2500 Bethyl Laboratories, Montgomery,
TX, USA
PARP1 1 : 1000 Cell Signaling, Frankfurt/Main,
GermanyBIM 1 : 2500
BAK 1 : 2500
BCL-XL 1 : 5000
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the ultrathin sections were stained with lead citrate
and photographically imaged in a Zeiss EM900 trans-
mission electron microscope (Carl Zeiss).
2.16. Freeze-fracture replica immunogold
labeling electron microscopy of p53
Sample preparation was done as described in Ref. [33].
The freeze-fracture replicas were imaged in a Zeiss
EM902A transmission electron microscope (Carl
Zeiss). Images were recorded with a 1k (1024 × 1024)
FastScan-CCD-camera (CCD-camera and the acquisi-
tion software EMMANU4 v 4.00.9.17, TVIPS, Munich,
Germany).
2.17. PTM analysis by mass spectrometry
2.17.1. Immunoprecipitation of p53
Protein G Dynabeads (Thermo Scientific) were cross-
linking with an equal volume of anti-p53 primary anti-
bodies [50 : 50 (v/v) DO-1 and Bp53-12; Santa Cruz]
with BS3 (Thermo Scientific) following the manufac-
turers’ instructions. Cells were harvested by scraping
in lysis buffer (50 mM Tris pH 7.5, 1 mM EDTA, 1%
(v/v) NP-40, 50 mM NaF, 5 mM sodium pyrophos-
phate, 0.27 M sucrose supplemented with protease inhi-
bitor complete (Roche, Basel, Switzerland), 10 µM
trichostatin A, 10 mM sodium butyrate, 10 mM nicoti-
namide, 1 mM sodium orthovanadate, 10 mM sodium
β-glycerophosphate) followed by brief sonication. Each
lysate was incubated with 30 µL of bead-antibody mix-
ture overnight at 4 °C. Afterward, beads were washed
twice with lysis buffer, once with high salt buffer
(20 mM Tris pH 8.1, 500 mM NaCl, 0.1% SDS, 1%
Triton X-100, 1 mM EDTA), and thrice with TBST
(0.05% Tween-20 in TBS). Precipitated p53 was eluted
from the beads for 10 min at 95 °C in 50 μL 1× LDS
buffer (Thermo Scientific). Supernatants were trans-
ferred into new tubes, and DTT was added (final con-
centration 20 mM). Samples were boiled 10 min at
95 °C, separated by SDS/PAGE, and stained with
Coomassie.
2.17.2. In-gel proteolytic protein digestion
The region containing p53 was excised from an SDS
gel and washed twice with 50 mM NH4HCO3, and
once 50 mM NH4HCO3 with 50% acetonitrile. Proteins
within the gel slices were reduced using 10 mM DTT
(54 °C, 30 min) and subsequently alkylated with
55 mM iodoacetamide (RT, 45 min). Gel pieces were
washed with 50 mM NH4HCO3, and 50 mM
NH4HCO3 with 50% acetonitrile and finally dehy-
drated using acetonitrile before drying in a SpeedVac.
Trypsin (5 μgmL−1 trypsin gold; Promega GmbH
(Walldorf, Germany); in 25 mM ammonium bicarbon-
ate) was added and incubated for 12 h at 30 °C. Tryp-
tic peptides were extracted from gel pieces with two
50% (v/v) acetonitrile/water washes and subsequently
dried in a SpeedVac.
2.17.3. Liquid chromatography
The tryptic digest obtained was separated by nanoscale
C18 reverse-phase liquid chromatography performed
on an EASY-nLC II (Thermo Scientific) coupled to a
Linear Trap Quadrupole—Orbitrap Velos mass spec-
trometer (Thermo Fisher). Elution was carried out
using a binary gradient with buffer A: 2% acetonitrile
and B: 80% acetonitrile, both containing 0.1% of for-
mic acid. Samples were resuspended and loaded with
buffer A, on a precolumn NS-MP-10 BioSphere C18
5 μm 120 Å– 360/100 μm × 0.2cm of length
(NanoSeparations), and washed with 25 µL of buffer
A at a maximum pressure of 200 bar. Desalted pep-
tides were subsequently eluted at 200 nLmin−1 flow,
into a 20 cm fused silica emitter (New Objective)
packed in-house with ReproSil Gold 200 C18, 3 μm
resin (Dr. Maisch GmbH, Ammerbuch, Germany).
The gradient used started at 5% of buffer B and was
increased to 28% over 42 min and then to 45% over
13 min. Finally, a washing step at 100% of B was car-
ried out over 10 min followed by a 5-min re-equilibra-
tion at 5% B for a total duration of 70 min. The
eluting peptide solutions were automatically (online)
electrosprayed into the mass spectrometer via a nano-
electrospray ion source. An Active Background Ion
Reduction Device (ABIRD) was used to decrease the
contaminant signal level.
2.17.4. Data-dependent acquisition
General mass spectrometric conditions were as follows:
Spray voltage, 2.4 kV, and ion transfer tube tempera-
ture, 200 °C. The mass spectrometer was operated in
positive ion mode and used in data-dependent acquisi-
tion mode (DDA). A full scan (FT-MS) was acquired
at a target value of 1 000 000 ions with resolution
R = 60 000 over a mass range of 350–1600 amu. The
top 10 most intense ions were selected for fragmenta-
tion in the linear ion trap using Collision Induced Dis-
sociation (CID) using a maximum injection time of
25 ms or a target value of 5000 ions. Multiply charged
ions from two to five charges having an intensity
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greater than 5000 counts were selected through a
1 amu window and fragmented using a normalized col-
lision energy of 35 for 10 ms. Former target ions
selected for MS/MS were dynamically excluded for
30 s.
2.17.5. Parallel reaction monitoring
Parallel reaction monitoring acquisition (PRM) was
used for the analysis of p53 acetylated peptides. A full
scan (FT-MS) was acquired at a target value of
1 000 000 ions with resolution R = 60 000 over a mass
range of 350–1600 amu followed by nine PRM scans
targeting the molecular masses of acetylated p53 pep-
tides present in the library and peptide 343–351 used
for normalization (Table 2). The precursor masses in
the PRM scans were fragmented using collision-in-
duced dissociation in the linear ion trap. Isolation
width of 1 m/z, the activation time of 10 ms, and nor-
malized collision energy of 36 were used to fragment a
maximum target of 5000 ions (or injection time of
25 ms). PRM scans mass ranges were adjusted accord-
ing to the masses of the monitored parent peptides.
PRM data were collected in triplicate.
2.17.6. Data-dependent analysis
Raw data were processed with Raw2MSN [34], and
Mascot generic files generated were analyzed using
MASCOT (Matrix Science Ltd, London, UK, version
2.4.1), querying both: SwissProt database (release
2014_01, restricted to Homo sapiens, 20 273 entries)
and an in-house database containing common pro-
teomic contaminants and main isoforms of human
p53. Mascot was searched assuming the digestion
enzyme trypsin allowing for two miscleavages with a
fragment ion mass tolerance of 0.5 Da and a parent
ion tolerance of 10 p.p.m. Cysteine carbamidomethy-
lation was specified in Mascot as a fixed modification.
Acetylation of protein N termini and lysine residues,
oxidation of methionine moieties, and phosphoryla-
tion of serine and threonine residues were specified in
Mascot as variable modifications. SCAFFOLD (version
4.3.2; Proteome Software Inc., Portland, OR, USA)
was used to validate MS/MS-based peptide and pro-
tein identifications. Peptide identifications were
accepted if they could be established at greater than
95.0% probability as specified by the Peptide
Prophet algorithm, resulting in a peptide false discov-
ery rate of 0.02% [35]. Only acetylated peptides still
present after filtering were used to build the library
used in PRM experiments.
2.17.7. Parallel reaction monitoring and quantitation
analysis
Normal and acetylated p53 tryptic peptides precursor
and fragment masses, used to setup PRM acquisition
methods, were deduced from a library generated using
data-dependent analysis data gathered from p53
immunoprecipitations. The PRM data traces of p53
acetylated tryptic peptides were used for MS/MS-based
quantitation. Raw data were imported into Skyline,
and y” and b product ions chromatograms of 1+ and
2+ charges were extracted, summed, and integrated.
Only fragment ion peaks with the same retention time
were used for quantitation. MS/MS filtering in Skyline
was applied to all replicates using: ‘Targeted’ acquisi-
tion method, product mass analyzer ‘QIT’ and resolu-
tion of 0.6 m/z. All matching scans were included in
data extraction. Ion series extracted were compared
using a 0.5 m/z tolerance to the 10 most intense pro-
duct ions of p53 acetylated peptides library; and dotp
values [36] obtained are reported in Table 2.
Table 2. Detected p53 fragments after tryptic digestion with corresponding acetylation site, charge, and m/z.
p53 peptide Sequence Ac. position m/z z Top 5 Monitored MS/MS peptide fragment DotP
292–305 (K)KGEPHHELPPGSTK(R) 292 519.2670 3 y6, y9++, y11++, y13++, b8++ 0.96
292–306 (K)KGEPHHELPPGSTKR(A) 305 571.3007 3 y6, y7++, y9++, b8, b9++ 0.86
307–320 (R)ALPNNTSSSPQPKK(K) 319 755.8966 2 y3, y5, y7, y12++, b11 0.93
307–320 (R)ALPNNTSSSPQPKK(K) 319 795.8798 2 y3, y5, y11++, y12++, b11 0.93
320–333 (K)KKPLDGEYFTLQIR(G) 321 875.4803 2 y9, y10, y12, y13++, b5 (Rt = 51.7) 0.92
320–333 (K)KKPLDGEYFTLQIR(G) 320 875.4803 2 y9, y10, y12, y13++, b5 (Rt = 50.8) 0.97
343–351 (R)ELNEALELK(D) none 529.7900 2 y3, y4, y5, y6, y7 0.98
380–386 (R)HKKLMFK(T) 381–382 516.2890 2 y5, y6, y6++, b2, b5 1.00
382–386 (K)KLMFK(T) 382 362.7067 2 y2, y3, y4, b2, b3 0.97
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2.18. Database analysis
Gene expression data and correlation coefficients
between gene expression and drug sensitivity in NCI-
60 cell line panel were exported using CellMiner web
tool [37]. Gene expression of TCGA dataset was ana-
lyzed using Gene_DE module in Timer web platform
[38].
2.19. Statistical analysis
Statistical analyses were done with Microsoft Excel
using a two-tailed Student’s t-test or with GRAPHPAD
(GraphPad Software, San Diego, CA, USA) using
one-way ANOVA test (*P < 0.05, **P < 0.01,
***P < 0.001). Error bars show standard error of the
mean (SEM) if not mentioned otherwise.
3. Results
3.1. Combinations of irinotecan and entinostat
induce apoptosis of p53-proficient cells
We studied how irinotecan, entinostat, and their com-
bination affect CRC cells. We measured the loss of the
mitochondrial membrane potential (δΨM), indicating
MOMP, and propidium iodide (PI) uptake, a marker
for cell death, by flow cytometry [29]. We incubated
HCT116wt/HCT116δp53 cells with 1–10 µM irinotecan
and 1–2 µM entinostat. These doses cover their thera-
peutic ranges in patients [21,23]. Several combinations
produced synergistic cytotoxic effects (CI < 1;
Fig. S1A,B, Table S1). Based on these data, we chose
2 µM entinostat and 5–10 µM irinotecan for our follow-
ing experiments. Ten micromolar irinotecan or 2 µM
entinostat caused up to 20% of ΨM loss and 20% PI-
positive cells in HCT116wt and HCT116δp53 cells.
Irinotecan plus entinostat significantly increased the
ΨM loss to 70% (P < 0.001) and cell death to 60%
(P < 0.01) in HCT116wt cells (Fig. 1A) but was
hardly more effective than the single agents in
HCT116δp53 cells (Fig. 1A, Fig. S1A,B). An analysis
of short-term cultured patient-derived CRC cells with
wild-type p53 (HROC24, HROC113, HHC6548) con-
firmed that a combined treatment with irinotecan plus
entinostat was superior over the single drugs
(Fig. S1C).
Immunoblot analyses showed that irinotecan plus
entinostat induced the accumulation of cleaved, active
caspase 3, and the cleavage of its target PARP1 [29] in
HCT116wt cells (Fig. 1B). The pan-caspase inhibitor
zVAD decreased the ΨM loss due to such treatment by
49% in HCT116wt cells (P < 0.05) (Fig. 1C,
Fig. S1D), confirming caspase-dependent apoptosis.
Flow cytometry analyses for cell cycle alterations
showed that after 24 h, irinotecan alone and combined
with entinostat induced an accumulation of cells in the
G2/M phase in HCT116wt and HCT116δp53 cells
(Fig. 1D). Entinostat p53 independently increased G1
and decreased S phase cell populations and increased
sub-G1 fractions (cells with DNA content < 2N). Sub-
G1 fractions increased to 11% in HCT116wt cells
(P < 0.001) and remained unaltered in HCT116δp53
cells (P < 0.01 to HCT116wt) that were exposed to
both agents. After 48 h, entinostat further reduced S
phase populations in HCT116wt (3%; P < 0.001) and
HCT116δp53 cells (6%; P < 0.01) (Fig. 1E). Irinotecan
increased G2/M (HCT116wt 73%; HCT116δp53 79%;
both P < 0.001) and decreased G1 phase populations
(HCT116wt 11.6%; P < 0.001; P < 0.01 to
HCT116δp53 6%). Irinotecan plus entinostat caused an
accumulation of 38% of HCT116wt cells in sub-G1
(P < 0.001; P < 0.01 to HCT116δp53) and fewer cells
arrested in G2/M (35%; P < 0.001 to HCT116δp53)
than upon irinotecan treatment. Irinotecan alone and
combined with entinostat caused similar effects in
HCT116δp53 cells.
Consistent with these flow cytometry data, we noted
that irinotecan increased and entinostat decreased the
mitosis-promoting cyclin B1. Moreover, the antiprolif-
erative cyclin-dependent kinase inhibitor (CDKi) p16
accumulated p53 independently in response to entinos-
tat (Fig. 1F). Another CDKi, p19, was unaffected by
these treatments. Irinotecan alone and combined with
entinostat decreased the phosphorylation of histone
H3 at serine 10, a G2/M maker, in both genotypes.
These data demonstrate that irinotecan activates the
G2/M checkpoint p53 independently.
The accumulation of p16 after entinostat (Fig. 1F)
and cell cycle arrest after irinotecan treatment (Fig. 1
D,E) did not evoke senescence after 24 h (Fig. S1E).
Few senescent (β-galactosidase-positive) cells appeared
in HCT116wt cells after a 48 h treatment with entinos-
tat and more prominently upon cotreatment with
irinotecan. However, most cells remained β-galactosi-
dase-negative (Fig. S1F).
Organoids from primary CRC tumors and xeno-
transplantation models represent predictive preclinical
models [39]. Interestingly, organoids from p53 wild-
type CRC and adjacent nonmalignant tissue revealed
that irinotecan plus entinostat significantly eliminated
tumor organoids but spared healthy tissue organoids
(P < 0.001 for treated tumor organoids to control and
to healthy organoids) (Fig. 1G,H). Using a BALB/c
cell transformation assay [32], we further noted that
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this drug combination reduced the number of malig-
nancy-associated type-III foci significantly (P < 0.01)
(Fig. S1G).
Transplantation of HROC24 cells into mice demon-
strated that irinotecan plus entinostat significantly
suppressed the growth of established CRC tumors
(P < 0.001 tumor volume; P < 0.01 tumor weight)
(Fig. 1I–K). This was not associated with a weight loss
of mice, and we observed no general toxicity judging
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These data show that irinotecan plus entinostat sig-
nificantly impairs the growth and survival of p53-posi-
tive CRC cells, transformed cell foci, tumor organoids,
and established tumors in mice.
3.2. Irinotecan plus entinostat causes DNA
damage and attenuates HR
Since HR is the main repair pathway that prevents
lethal DNA damage upon TOP1 inhibition [21,22,40],
we considered that apoptosis was associated with a
dysregulation of HR proteins by irinotecan plus entino-
stat. We investigated such proteins and found that
irinotecan induced the phosphorylation of the check-
point kinases ATM (pATM) and ATR (pATR), of
RPA (pRPA), and increased the levels of BRCA1 and
RAD51. Entinostat decreased BRCA1 and RAD51
below basal levels and attenuated pATR and pATM in
response to irinotecan, with stronger effects in
HCT116wt cells than in HCT116δp53 cells (Fig. 2A).
After 48 h, these inhibitory effects of entinostat on HR
proteins became more obvious (Fig. 2B). Contrary to
HCT116wt cells, HCT116δp53 cells maintained ATM
and BRCA1. Entinostat decreased the mRNAs of
RAD51, BRCA1/BRCA2, and FANCD2 in HCT116wt
and HCT116δp53 cells (Fig. 2C).
Checkpoint kinases catalyze the phosphorylation of
histone H2AX (γH2AX) [21]. Immunofluorescence for
γH2AX foci and their colocalization with the DNA
repair proteins 53BP1 (indicating DNA double-strand
breaks) or RAD51 (indicating HR foci) revealed that
irinotecan induced foci of 53BP1/RAD51 with γH2AX
comparably in HCT116wt and HCT116δp53 cells (Fig. 2
D,E, Figs S2A,B and S3; γ-irradiation as positive con-
trol). Entinostat slightly induced γH2AX foci (Fig. 2D,
E). Irinotecan plus entinostat evoked pan-γH2AX stain-
ing in HCT116wt cells, a sign of apoptosis [41], and
reduced the number of γH2AX foci that colocalized
with 53BP1/RAD51 (Fig. 2D, Fig. S2A,B). HCT116δp53
cells still had these foci after such treatment and the
number of pan-γH2AX-stained cells was smaller than
in HCT116wt cells (Fig. 2E, Fig. S3). As in HCT116wt
cells, γH2AX accumulated in HROC24 cells (Fig. S2C).
We conclude that irinotecan plus entinostat evokes
significantly more DNA lesions in p53-proficient than
in p53-negative CRC cells.
3.3. Irinotecan plus entinostat modulates p53
PTMs
Since PTMs critically control p53 [13,17], we analyzed
their regulation by irinotecan plus entinostat.
Fig. 1. Irinotecan plus entinostat induces apoptosis in p53-proficient CRC cells, CRC organoids, and established CRC tumors. HCT116wt and
isogenic HCT116Δp53 cells were exposed to 10 µM irinotecan (Iri), 2 µM entinostat (MS, short for MS-275, the alterative name of entinostat),
and their combination (Iri+MS). (A) The percentages of cells with disrupted mitochondrial transmembrane potential (loss of ΔΨM) and dead
cells (accumulation of PI) were quantified by flow cytometry after 48 h. (B) Immunoblot shows the levels of the indicated proteins after
48 h; α-tubulin verifies equal protein loading (cl., cleaved). (C) Cells were 1 h pretreated with 20 µM zVAD alone  Iri+MS for 48 h. Loss of
ΔΨM was quantified by flow cytometry. (D, E) HCT116wt and HCT116Δp53 cells were exposed to 5 µM Iri  2 µM MS. The cells were tested
for nuclear PI contents that mirrors cell cycle distributions after 24 h (D) and 48 h (E) by flow cytometry. (F) Expression levels of indicated
proteins were analyzed by immunoblot after 24-h treatment with 10 µM Iri  2 µM MS. α-tubulin serves as a loading control. Due to the
similar sizes of p16 and p19, these were probed on individual membranes. (G) Human organoid cultures from healthy and tumor tissue of
one patient with known p53 status were exposed for 24 h to 10 µM Iri + 2 µM MS. The amount of intact, living organoids was assessed by
microscopy (H). All graphs show the mean value of three independent experiments  SEM; immunoblots are representative for three
independent experiments. (I) 6- to 8-week-old NMRI-Foxn1nu mice were treated with solvent (control) or 20 mgkg−1 irinotecan in
combination with 2.5 mgkg−1 MS-275 for 16 days. Changes in tumor volume were monitored daily. The graphs show the mean value of 4
control and 6 Iri+MS-treated tumors  SEM; statistic analysis here was done with one-way ANOVA. (J) The weight of resected tumors was
documented after 16 days, and representative pictures are shown in (K). Significances for this figure are: *P < 0.05; **P < 0.01;
***P < 0.001 using two-tailed t-tests in (A), (C), (H), and (J) or one-way ANOVA test in (I).
Fig. 2. Impaired homologous repair after irinotecan plus entinostat combination in HCT116wt cells. HCT116wt and HCT116δp53 cells were
exposed to 10 µM irinotecan (Iri)  2 µM entinostat (MS, short for MS-275). Expression levels of indicated proteins were analyzed by
immunoblot after 24 h (A) and 48 h (B). α-tubulin was used to control protein loading. The mRNA expressions of indicated genes (C) were
quantified by qRT-PCR after 24 h. HCT116wt (D) and HCT116δp53 (E) cells were exposed to 10 µM Iri  2 µM MS for 24 h or irradiated with
2 Gy for 2 h before fixation. The expression and localization of 53BP1 (green; upper panels) or RAD51 (green; lower panels) together with
γH2AX (red) was analyzed by fluorescence microscopy. DAPI was used as a nuclear stain. Scale bars are equal to 10 µm. All graphs show
the mean value of independent experiments  SEM; immunoblots and microscopy pictures are representative of three independent
experiments.
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Irinotecan strongly induced p53 protein expression
(threefold) and acetylation of its lysine residues 373
(acK373; 2.5-fold), 382 (acK382; 11.6-fold), 381
(acK381, 1.9-fold), and 305 (acK305, 4.5-fold). Enti-
nostat increased the acetalytion of p53, but did not
change p53 levels (Fig. 3A–C, Fig. S4A,B). Cotreat-
ment of cells with both agents further increased
C-terminal acK373-, acK381-, and acK382-p53
(4.4-fold; 3.2-fold; and 22.8-fold); total p53 and
acK305-p53 were expressed as in irinotecan-treated
cells.
p53 was also strongly acetylated at K382 in CRC
organoids (2.3-fold), RKO, HROC24, and HHC6548
CRC cells after treatment with irinotecan plus entinos-
tat (Fig. 3D, Fig. S4C,D). This finding indicates a gen-
eral induction of this PTM by this drug combination.
To obtain a comprehensive view on p53 acetylation,
we analyzed p53 immunoprecipitates by mass spec-
trometry (Fig. 3E,F). Analysis of tryptic peptides from
purified p53 disclosed that irinotecan induced the
acetylation of K292, K305, K319/320, K320, K321,
K381/382, and K382. Irinotecan plus entinostat partic-
ularly increased the acetylation of the C-terminal
K381/382 and K382 residues (P < 0.05 to irinotecan)
(Fig. 3F), with acK382 being the most abundant
PTM. Therefore, we used acK382 as general but not
exclusive marker for p53 C-terminal acetylation in the
following experiments.
3.4. Entinostat modulates p53 and BCL2 family
members
N-terminal phosphorylation of p53 regulates its tran-
scriptional activity [13,17]. Irinotecan induced p53 phos-
phorylation at serine 15 (pS15; 14.3-fold) (Fig. 4A).
Contrary to the increased C-terminal acetylation, enti-
nostat decreased pS15-p53 (9.2-fold) in irinotecan-treated
HCT116wt cells (Fig. 4A,B). This made us analyze the
relationship between PTMs and targets of p53. Irinote-
can induced the protein levels of p21 and HDM2 in
HCT116wt but not in HCT116δp53 cells. This was abro-
gated by entinostat (Fig. 4A, Fig. S4E).
Congruently, irinotecan elevated the mRNA expres-
sion of the p53 target genes BAX (1.3-fold), HDM2
(1.3-fold), CDKN1A (p21; 6.9-fold), TP53I3 (PIG-3;
5.7-fold), and BBC3 (PUMA; 3.3-fold). Entinostat
reduced these effects (Fig. 4C). None of these genes
were induced in HCT116δp53 cells, except for
CDKN1A. p21 was though barely detectable by immu-
noblot in such cells (Fig. 4A, Fig. S4E).
We further analyzed the mRNA levels of BCL2L11
(BIM), BAK1, BCL2, BCL2L1 (BCL-XL), and BID,
which are apoptosis regulators of the BCL2 family [14].
BID, BCL2L1 mRNAs, and the BCL-XL protein were
unaffected by irinotecan (Fig. 4D,F). Entinostat and
irinotecan plus entinostat increased BCL2, BCL2L11
mRNA, and BIM protein levels particularly in
HCT116wt cells (Fig. 4A,D, Fig. S4E). Entinostat alone
and in combination with irinotecan reduced BCL2L1
and BID mRNAs, and BCL2 and BCL-XL proteins in
both HCT116 cell lines (Fig. 4D–F). BAK1 was slightly
induced by all treatments in both genotypes (Fig. 4D).
Thus, entinostat induced fundamental changes of
BCL2 proteins—a p53-independent decrease in BCL2
and BCL-XL and a p53-dependent increase in BIM.
To study whether the reduction in antiapoptotic
BCL2 proteins by entinostat is a mechanism for apop-
tosis induction, we combined the BCL2/BCL-XL/
BCL-W inhibitor navitoclax (ABT-263) [19] with
irinotecan. Navitoclax and irinotecan alone moderately
inceased the amount of apoptotic HCT116wt cells
(Fig. 4G). Irinotecan plus navitoclax significantly
induced apoptosis in HCT116wt but not in
HCT116δp53 cells (60–69% for 5–10 µM irinotecan plus
navitoclax; each P < 0.001 to irinotecan and to p53
cells). We could reproduce this finding in HROC24
cells (Fig. S4F). As expected for a nondegrading inhi-
bitor [19], the proapoptotic effects of irinotecan plus
navitoclax were not linked to a loss of BCL-XL
(Fig. S4G).
Fig. 3. The irinotecan/entinostat cotreatment induces specific p53 acetylation patterns and apoptosis. HCT116wt and HCT116Δp53 cells were
exposed to 10 µM irinotecan (Iri)  2 µM entinostat (MS, short for MS-275) for 24 h. (A) Levels of indicated proteins and acetylation of p53
were analyzed by immunoblot after 24 h. HSP90 and α-tubulin are loading controls. Quantification of p53 acetylation was done by IMAGEJ;
the ratios of acetylated over total p53 for lysine 373 (acK373) and 382 (acK382) (B) were calculated. Quantification of total p53 level is
shown in (C). (D) Levels of p53 acetylation in human tumor organoid cultures were analyzed by immunoblot after 24-h treatment.
Quantification of corresponding p53 acetylation and total p53 level was done by IMAGEJ. Acetylation of lysine residues 292 (acK292), 305
(acK305), 320 (acK320), 321 (acK321), 319, and 320 (acK319 & acK320) (E) as well as acetylation of lysine moieties 381 and 382 (acK381
and acK382) and 382 (acK382) (F) were detected in different protein fragments of p53 by targeted liquid chromatography electron spray
ionization mass spectrometry (LC-ESI-MS). Levels of each modification were shown relative to a global standard (p53 tryptic peptide 343–
351). (A, B, D) show the mean value of two independent experiments  SEM. (C, E, F) show the mean value of four independent
experiments  SEM. Significances for this figure are: *P < 0.05; **P < 0.01; ***P < 0.001 using two-tailed t-tests.
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Fig. 4. Entinostat alters the expression of BCL2 family members to promote apoptosis. HCT116wt and HCT116Δp53 cells were exposed to
10 µM irinotecan (Iri)  2 µM entinostat (MS, short for MS-275). Levels of indicated proteins and phosphorylation of p53 were analyzed by
immunoblot after 24 h. HSP90 and α-tubulin are loading controls. Quantification of p53 phosphorylation was done by IMAGEJ; the ratio of
phosphorylated (pS15-p53) over total p53 (B) was calculated. (C) The mRNA expression of indicated genes were quantified by qRT-PCR
after 24 h. (D) Expression level of BCL2 was analyzed by immunoblot after 24 h. HSP90 served as loading control. HCT116wt cells were
exposed to 5 µM Iri  2 µM MS. (E) Expression level of BCL-XL was analyzed by immunoblot after 24 and 48 h. Vinculin served as loading
controls. HCT116wt and HCT116Δp53 cells were exposed to 5–10 µM Iri  500 nM ABT-263 (ABT; navitoclax) for 48 h. The percentage of
apoptotic, annexin-V-positive cells was quantified by flow cytometry afterward. (A–F) show the mean value of two independent
experiments  SEM. (G) shows the mean value of three independent experiments  SEM. Significances for this figure are: *P < 0.05;
**P < 0.01; ***P < 0.001 using two-tailed t-tests.
14 Molecular Oncology (2021) ª 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
Acetyl-p53-BAK complexes induce MOMP upon RS C. Marx et al.
These data illustrate that irinotecan activates the
transcriptional activity of p53. Entinostat antagonizes
this effect and decreases BCL2 protein levels. An inhi-
bition of antiapoptotic BCL2 proteins in cells with RS
induces apoptosis p53 dependently.
3.5. Acetylated p53 accumulates at mitochondria
after application of irinotecan and entinostat
Since there is a loss of ΨM in p53-proficient cells in
response to a treatment with irinotecan and entinostat
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(Fig. 1A,B), we analyzed mitochondrial morphology
by transmission electron microscopy (TEM) (Fig. 5A,
Fig. S5A). HCT116wt cells had bean-shaped mitochon-
dria with intact cristae. After irinotecan treatment,
mitochondria were smaller and spherical. Irinotecan
plus entinostat increased such mitochondrial damage
and degradation (Fig. 5A). HCT116δp53 cells showed
less severe mitochondrial defects (Fig. S5A), confirm-
ing ΨM measurements (Fig. 1A).
Transmission electron microscopy and mitochon-
drial fractionation followed by immunoblot revealed
that p53 was present at mitochondria in untreated cells
(Fig. 5B–D, Fig. S5B). Irinotecan caused a strong
accumulation of p53, pS15-p53, and acK382-p53 in
both mitochondrial and cytosolic compartments.
Irinotecan plus entinostat increased acK382-p53 and
decreased pS15-p53 levels without an effect on total
p53 (Fig. 5B–D). Intriguingly, acK382-p53 accumu-
lated more in mitochondrial than in cytosolic fractions
when we applied irinotecan plus entinostat (Fig. 5B).
This suggests that acK382-p53 prominently locates to
and interacts with proteins at mitochondria. Similar
observations in RKO and HROC113 cells (Fig. S5C–
H) show a general accumulation of mitochondrial
(mt)-acK382-p53 and depletion of mt-pS15-p53 in
CRC cells that are treated with irinotecan plus entino-
stat. We further found that p53 and acK382-p53 local-
ized at the mitochondrial membrane and matrix after
this treatment (Fig. 5E).
Moreover, irinotecan increased the levels of mitochon-
drial BCL-XL and BIM. Addition of entinostat to
HCT116wt, RKO, and HROC113 cells that were
cotreated with irinotecan decreased BCL-XL and BAX
but further increased BIM (Fig. 5B, Fig. S5C,F,I). More-
over, BIM accumulated at mitochondrial membranes
and cytochrome c was released from the mitochondrial
intermembrane space into the cytosol after irinotecan
plus entinostat (Fig. 5E), indicatingMOMP [14].
K120 acetylation of p53 promotes its interactions
with HDM2, BCL2 proteins, and apoptosis induction
upon DNA damage [16,25]. Entinostat and camp-
tothecin (irinotecan is the clinically approved deriva-
tive thereof) induce acK120-p53 in lung and breast
tumor cells [16]. In our study, acK120 escaped detec-
tion by mass spectrometry. To still understand the role
of acK120-p53, we used human p53-negative H1299
non-small-cell lung cancer cells with a tetracycline-in-
ducible expression of p53wt or p53K120R, which cannot
be acetylated at K120 [25]. Both p53wt and p53K120R
translocated to mitochondria after treatment with
irinotecan alone or with entinostat. However, acK382-
p53 was only induced by irinotecan plus entinostat
(Fig. S5J–K). ΨM loss was higher in p53wt than in
p53K120R and noninduced H1299 cells after irinotecan
treatment. While irinotecan plus entinostat induced a
comparable ΨM loss in H1299 cells with p53wt and
p53K120R (86.6% and 66.9%); noninduced H1299 cells
were even less affected than with irinotecan (27.5%)
(Fig. S5L), suggesting that the acetylation of K120 is
not required for the synergistic apoptosis induction by
irinotecan and entinostat.
This finding encouraged us to further analyze the
C-terminal acetylation of p53. Since Entinostat attenu-
ated p53 target gene expression upon irinotecan-
induced RS (Fig. 4), we hypothesized that the C-terminal
acetylation of p53 promoted its interaction with
BCL2 proteins. The activation and oligomerization of
BAK by p53 can induce MOMP [14,20]. Therefore,
we immunoprecipitated BAK, as well as BCL-XL,
which binds and inactivates proapoptotic BCL2 pro-
teins [14]. Irinotecan alone and in combination with
entinostat induced clearly and specifically detectable
p53-BAK and p53-BCL-XL complexes (Fig. 5F,G).
Entinostat alone just slightly induced these protein–
protein interactions. Notably, p53 in the p53-BAK
and p53-BCL-XL complexes was acetylated at K382
only in cells that were treated with both irinotecan
and MS-275.
We deduce that C-terminally acetylated p53 and
BIM accumulate at mitochondria and that acK382-
Fig. 5. Irinotecan plus entinostat induces C-terminal acetylation of p53 and mitochondrial damage. HCT116wt cells were exposed to 10 µM
irinotecan (Iri)  2 µM entinostat (MS, short for MS-275) for 24 h. (A) Mitochondrial morphologies were analyzed by TEM. Representative
mitochondria are shown enlarged in the top left corner of each panel. Black arrows indicate damaged mitochondria. Scale bars are equal to
2 µm. (B) Cell lysates were fractionated into mitochondria and cytosol. The expression of indicated proteins, localization, and modification of
p53 was analyzed by immunoblot. HSP90 and ATP5A (ETC complex V) served as protein loading control within individual compartments.
Quantification of corresponding p53 PTMs was done by IMAGEJ; the ratios of mitochondrial (mt) pS15- and mt-acK382- over total mt-p53 (C)
were calculated. Quantification of total mt-p53 level is shown in (D). (E) Mitochondria were further fractionated into their membranes and
matrixes by NaCO3 treatment. The expression and localization of indicated proteins and acetylation of p53 were analyzed by immunoblot.
HSP90, TOM40, and ATP5A served as loading controls for the compartments. BCL-XL (F) and BAK (G) were immunoprecipitated from cell
lysates, and expression levels of indicated proteins and acetylation of p53 were analyzed by immunoblot. (A–G) are representative/show the
mean value of two independent experiments  SEM; # indicates long exposure of the immunoblots shown in (F, G).
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p53 binds to BAK and BCL-XL in cells that are incu-
bated with irinotecan plus entinostat.
3.6. C-terminal acetylation of p53 by CBP/p300 is
key for apoptosis induction during RS
The results above suggest that C-terminal acetylation
of p53 triggers MOMP. The HATs CBP and p300
acetylate and HDAC1, −2, and −3 deacetylate the C
terminus of p53 [13,17]. Using the CellMiner online
platform [37], we investigated the expression patterns
of these enzymes in 60 cancer cell lines of various ori-
gins (Tables S2 and S3). We noted lower mRNA tran-
script levels of CREBBP (encodes CBP) and more
frequently of EP300 (encodes p300) (z-value < 0) and
higher transcript levels of HDAC1, HDAC2, and
HDAC3 mRNAs in CRC cells (Table S2). Moreover,
CRC cells have particularly high mutation rates in
CREBBP and EP300 genes when compared to other
cancer cell types (Table S3).
Analyzing The Cancer Genome Atlas (TCGA) [38],
we found significantly lower CREBBP and EP300
expression in tumors of patients with colon adenocar-
cinoma (COAD) and rectum adenocarcinoma (READ)
compared with matched nonmalignant tissues
(Fig. S6A,B). Again, HDAC1,-2,-3 mRNA transcripts
were significantly overexpressed in COAD and READ
samples (Fig. S6C–E). Concerning BCL2 family genes,
we found significantly lower levels of BCL2 and
BCL2L11 and significantly higher BCL2L1 expression
in COAD and READ than within matched nonmalig-
nant tissues (Fig. S7), suggesting physiologically rele-
vant functions of BCL-XL and BIM in CRC tumors.
The low abundance of CBP/p300 transcripts, their
high degree of mutations, and the high expression of
HDACs targeting the p53 C terminus in CRC suggests
that such cells require low levels of acetylated p53 for
survival. Therefore, we analyzed the relevance of CBP/
p300 with their novel inhibitor CPI-1612 [24]. In cells
treated with irinotecan plus entinostat, CPI-1612 dose
dependently suppressed the acetylation of p53 at K382
and did not reduce total p53, pS15-p53, or histone H3
acetylation (Fig. 6A). These data verify the specificity
of CPI-1612, which equally suppressed the accumula-
tion of acK382-p53 in irinotecan plus entinostat-trea-
ted RKO, HROC24, and HHC6548 CRC cells
(Fig. S8A,B). Likewise, CPI-1612 abolished acK382-
p53 levels in cytosolic and mitochondrial fractiona-
tions of HCT116wt, RKO, HROC24, and HROC113
cells (Fig. 6B,C, Fig. S8C–H). The stabilization and
mitochondrial accumulation of p53 in response to
irinotecan plus entinostat were though not reduced by
CPI-1612.
Functional analyses demonstrated that CPI-1612
prevented the cleavage of PARP1 and reduced cas-
pase-3 activation in HCT116wt but not in HCT116δp53
cells that were treated with irinotecan plus entinostat
(Fig. 6D). CPI-1612 also suppressed apoptosis induc-
tion by this drug combination in HROC24 cells
(Fig. S8I) and CPI-1612 significantly lowered the num-
ber of apoptotic cells in HCT116wt and RKO cells that
were treated with irinotecan plus navitoclax (Fig. S8J,
K). These data show that CPI-1612 has an antiapop-
totic effect in CRC cells expressing p53 and that the
C-terminal acetylation of p53 is more crucial to trigger
apoptosis than changes in BCL2 proteins.
To complement these data, we stably reconstituted
HCT116δp53 cells with p536KR, which cannot be acety-
lated at its C terminus (Fig. S8L). p536KR accumulated
in response to irinotecan or entinostat, with strongest
effects seen with their combination (Fig. 6E,F). Mea-
surement of ΨM loss revealed that p536KR did not sen-
sitize cells to irinotecan plus entinostat (Fig. 6G) and
CPI-1612 did not reduce the levels of cleaved PARP1
and caspase-3 in stable p536KR and EV-transfected
HCT116 cells that were treated with these agents
(Fig. S8M). Nonetheless, p536KR accumulated at mito-
chondria after treatment (Fig. S8L). Hence, C-terminal
acetylation of p53 is not essential for its mitochondrial
accumulation but for apoptosis induction.
As CPI-1612 suppressed apoptosis induction by
irinotecan plus entinostat or navitoclax, we speculated
that C-terminally acetylated p53 interacts with regula-
tors of mitochondrial apoptosis. Again, we immuno-
precipitated BAK and BCL-XL and tested for bound
p53 and acK382-p53. CPI-1612 abolished the C-termi-
nal acetylation of p53, and consequently, the presence
of acK382-p53 in BAK and in BCL-XL complexes in
HCT116 cells (Fig. 6H,I). Total p53 was though still
bound to BAK or BCL-XL. These observation were
confirmed in HROC24 and RKO cells (Fig. S9), illus-
trating a general mechanism in CRC cells and the
necessity of p53-BAK and p53-BCL-XL complexes
containing C-terminally acetylated p53 for MOMP-dri-
ven apoptosis.
These data define a novel acetylation-dependent
pathway of p53-mediated mitochondrial apoptosis in
CRC cells. The modulation of antiapoptotic BCL2
proteins by entinostat does not kill CRC cells with RS
in the absence of C-terminally acetylated p53, which
binds BAK and BCL-XL. Hence, this acetylation of
p53 is a key trigger for apoptosis upon RS and HDAC
inhibition. This notion extends the perspective on how
p53 initiates apoptosis, since until now its accumula-
tion at mitochondria and acetylation within its DBD
are believed to trigger MOMP [12,15,20].
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4. Discussion
Late-stage CRC requires novel therapies [42]. We show
that combinations of irinotecan plus entinostat effi-
ciently kill p53-positive CRC cells that grow in vitro
and in vivo as well as malignant cell foci formation
and CRC tumor organoids, illustrating translational
relevance. Moreover, our data suggest that class I
HDAC inhibition allows reducing the doses of irinote-
can that need to be given to patients. This is of clinical
relevance because irinotecan is a frequently applied
drug that, unfortunately, produces severe side effects
that lead to a discontinuation of its use [21,23].
We observed that irinotecan induced various PTMs
of p53, including the acetylation of several lysine resi-
dues and N-terminal phosphorylation. In parallel, we
found elevated p53 target gene expression, activated
caspase-3, and cleaved PARP1 in irinotecan-treated
HCT116wt cells. Entinostat specifically increased the
irinotecan-induced acetylation of the C-terminal p53
residues K373, K381, and K382 in CRC cells and
organoids with strongest effects on K382. Other acety-
lation sites of p53 in the tetramerization domain
(K292, K305, K320) were not altered upon the addi-
tion of entinostat. While this does not imply that
acetylated K373 and K381 are less important for
apoptosis induction than acetylated K382, we can con-
nect increased mitochondrial acK382-p53 levels to
MOMP induction and apoptosis of cells that are trea-
ted with combinations of irinotecan plus entinostat. A
role of C-terminally acetylated p53 and its relevance
for irinotecan-induced apoptosis have not been
described before. Such insights are relevant in light of
the sparsely defined molecular markers for therapeutic
effects of HDACi alone and when combined with
standard chemotherapeutics [2,7,43]. Apparently, the
presence of C-terminally acetylated p53 promotes the
proapoptotic activity of BAK and impairs the anti-
apoptotic functions of BCL-XL and CBP/p300 and
HDAC1,-2,-3 are antagonistic gatekeepers of this
process.
We further demonstrate that the acetylation of the
p53 C terminus does not significantly alter the mito-
chondrial localization of p53 and its interaction with
BAK and BCL-XL. These data are coherent to the
current literature which reports that the binding of
these proteins is mediated through the p53 DBD
[16,17,20,44–47]. Nonetheless, the presence of acK382-
p53 in BAK and BCL-XL complexes appears decisive
for whether irinotecan plus entinostat induces apopto-
sis. This finding confirms the notion that p53-BAK
and p53-BCL-XL complexes trigger apoptosis
[12,13,20] and we present a pharmacologically feasible
way to enhance the apoptotic activity of this complex.
The acetylation of p53 at K120 (within its DBD) does
not determine its interaction with BCL-XL and does
not activate BAK directly but replaces it from MCL-1
to initiate apoptosis [16,20,25]. In accordance herewith,
we show that K120 is important for p53’s functions
after irinotecan treatment. However, it is not essential
for the mitochondrial translocation of p53, its stability,
and MOMP induction after irinotecan plus entinostat
treatment. We provide evidence that the C-terminally
acetylated p53 which binds BAK and BCL-XL is deci-
sive for apoptosis induction. Congruent herewith,
p536KR cannot enhance apoptosis in irinotecan plus
entinostat-treated cells compared with irinotecan,
although these drugs stabilize p536KR.
We further discriminate how the acetylation of p53
in cells with RS affects its ability to induce apoptosis
Fig. 6. CBP/p300 activity is necessary to acetylate the C terminus of p53 and to induce apoptosis. HCT116wt were exposed to 10 µM
irinotecan (Iri) + 2 µM MS-275 (MS)  25–1000 nM CPI-1612 (CPI) for 24 h. (A) Levels of indicated proteins and PTMs of p53 were analyzed
by immunoblot. β-actin served as loading control. HCT116wt and HCT116Δp53 cells were exposed to 10 µM Iri + 2 µM MS  200 nM CPI-
1612. (B, C) Cell lysates were fractionated into mitochondria and cytosol after 24 h. The expression of indicated proteins, localization, and
acetylation of p53 was analyzed by immunoblot (B). HSP90 and ATP5A served as protein loading controls within individual compartments.
Quantification of p53 acetylation was done by IMAGEJ; the ratios of mitochondrial (mt) acK382- over total mt-p53 (C) were calculated, and the
expression of total mt-p53 is shown. (D) Levels of indicated proteins were analyzed by immunoblot after 48 h. Vinculin served as loading
control. Stably transfected HCT116Δp53 cells expressing either empty vector (Δp53-EV) for control or an acetylation incompetent p536KR
mutant protein (Δp53-p536KR) were exposed to 10 µM Iri  2 µM MS. (E) Levels of p53 were analyzed by immunoblot after 24 h and
quantified by IMAGEJ and are shown in (F); α-tubulin served as loading control. HCT116wt, HCT116Δp53, and stably transfected HCT116Δp53
expressing either EV or p536KR were exposed to 10 µM Iri  2 µM MS. (G) The loss of ΔΨM and cell death were quantified by flow
cytometry after 48 h. HCT116wt and HCT116Δp53 cells were exposed to 10 µM Iri + 2 µM MS  200 nM CPI-1612. BCL-XL (H) and BAK (I)
were immunoprecipitated from cell lysates, and expression levels of indicated proteins and acetylation of p53 were analyzed by immunoblot
afterward. (A–F) and (H, I) are representative/show the mean value of two independent experiments  SEM. # indicates long exposure of
the immunoblots shown in (H, I). (G) shows the mean values of four independent experiments  SEM. Significances for this figure are:
*P < 0.05; **P < 0.01; ***P < 0.001 using two-tailed t-tests.
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as transcription factor. Although the C-terminal acety-
lation can increase the promotor binding specificity of
p53 [48,49], entinostat lowered the irinotecan-induced
N-terminal phosphorylation of p53 and the induction
of its target genes in our systems. These lower pS15-
p53 levels might be explained by a reduced activation
of the checkpoint kinases ATM and ATR, which
phosphorylate p53 [8,13,17], in entinostat-treated cells.
Recent data consistently demonstrate that the acetyla-
tion of p53 is more critical than its nuclear abundance,
promoter binding, and stability [47,50,51].
Our finding that the CBP/p300 inhibitor CPI-1612
suppresses C-terminal acetylation of p53 in irinotecan
plus entinostat-treated CRC cells and consequently
apoptosis supports our model of a proapoptotic switch
that depends on C-terminal acetylation of p53. We
could confirm the specificity of CPI-1612 by a lack of
effect on histone acetylation, which is catalyzed by sev-
eral HATs [1,6]. Furthermore, we present evidence
that p53 is critical for the biological effects of CPI-
1612. This agent strongly attenuated apoptosis induc-
tion by irinotecan plus entinostat in HCT116wt,
HROC24, and RKO but not in HCT116δp53 and
p536KR-reconstituted cells, excluding p53-independent
antiapoptotic effects.
Irinotecan evokes RS and lethal DNA damage upon
prolonged replication fork stalling and if DNA lesions
are not repaired [21]. Our applied concentration range
of irinotecan alone had very similar, moderate cyto-
toxic effects on HCT116wt and HCT116δp53 cells, indi-
cating that such apoptosis induction can occur even in
the absence of p53. Others likewise noted that p53-
positive fibroblasts and glioma cells are even less sensi-
tive to DNA damage and apoptosis induction by
irinotecan. These authors suggested that a p53-depen-
dent proteasomal degradation of the TOP1 complex
on DNA prevents that stalled replication forks turn
into proapoptotic DNA strand breaks [52]. HCT116wt
and HCT116δp53 cells respond also very similarly to
entinostat [29]. We noted a p53-independent accumula-
tion of HR proteins, including RAD51 and that
proapoptotic effects of irinotecan plus entinostat in
p53-positive cells corelate with low HR protein and
mRNA levels. This occurs more strongly in HCT116wt
than in HCT116δp53 cells, indicating a suppression of
DNA repair by acetylated p53. Entinostat decreased
the irinotecan-induced RAD51 and 53BP1 foci in
HCT116wt cells and induced apoptosis-associated pan-
nuclear γH2AX. In p53-negative cells, RAD51 and
53BP1 foci remained present after irinotecan plus enti-
nostat and cells carrying pan-nuclear γH2AX were
low. This indicates a link between functional HR and
suppression of apoptosis. The early impact of p53 on
RAD51 protein expression appears to support the
apoptosis induction after the irinotecan-induced RS
and DNA damage. This might also apply to the loss
of BRCA1, full-length PARP1, and the attenuation of
pATM/pATR. The latter might be due to the induc-
tion of the phosphatase-2A subunit PR130 [8]. We fur-
ther show that entinostat attenuates BCL-XL
expression, probably reflecting an abrogation of the
RS-induced NF-κB/p53 crosstalk by HDACi [53].
Entinostat additionally attenuates BCL2 similar to
BCL-XL, which both inactivate BAK [14,20]. Hence,
their reduction in company with p53-BCL-XL complex
formation can promote p53-mediated BAK oligomer-
ization and MOMP induction. p53-mediated apoptosis
induction via PUMA and NOXA requires BIM, which
can, similar to p53, release BAK form antiapoptotic
BCL2 proteins [54,55]. BBC3 and BCL2L11 mRNAs
and BIM protein levels increase in HCT116wt cells that
are incubated with irinotecan plus entinostat but not
in HCT116δp53 cells. This suggest that the p53-PUMA-
BIM-axis contributes to apoptosis in irinotecan plus
entinostat-treated cells.
A major finding of this work is that a complex of
BAK with C-terminally acetylated p53 is a CBP/p300-
dependent, previously unknown master switch for
MOMP and apoptosis. As long as HDAC1,-2,-3 are
active, they prevent the formation of the complex con-
taining C-terminally acetylated p53 and BAK. Since
RS and DNA damage also occur endogenously in
rapidly growing cancer cells [56], such cells should be
selected for low CBP/p300 and high HDAC1,-2,-3
expression. Are there hints for a physiological rele-
vance for the regulation of p53 C-terminal acetylation
by class I HDACs and CBP/p300? Indeed, large-scale
analysis of tumor samples illustrates that CBP/p300
are low and that HDAC1, 2, 3 are highly expressed in
primary CRC tumors and CRC cell lines. This indi-
cates that a physiologically important function of p53
acetylation is to impair the development, growth, and
survival of CRC. A dysregulation of HDACs and
HATs could disengage C-terminal acetylation of p53
as an antitumorigenic apoptotic principle.
5. Conclusion
From our data, we deduce that an accumulation of C-
terminally acetylated p53 at mitochondria, its direct
interactions with BCL2 family proteins, and a shift of
antiapoptotic toward proapoptotic BCL2 family pro-
tein/gene expression upon class I HDAC inhibition
pushes cells with RS into apoptosis. Combinations of
irinotecan plus entinostat drastically cause mitochon-
drial injury and DNA damage in p53-positive cells.
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This is connected to (a) high C-terminal acetylation
and mitochondrial localization of p53, (b) acetyl-p53-
BAK and acetyl-p53-BCL-XL complexes, (c) impaired
HR and DNA repair, (d) decreased transcriptional
activity of p53, (e) an imbalance in BCL2 proteins,
and (f) significant intrinsic apoptosis induction in p53-
positive cancer cells. Thus, combinations of irinotecan
plus entinostat might be a promising therapeutic
approach for primary tumors and recurrent irinotecan-
resistant tumors.
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Fig. S1. Irinotecan plus entinostat is effective against
CRC cells and tolerated by mice.HCT116wt (A) and
HCT116δp53 (B) cells were exposed to 1-20 µM irinote-
can (Iri)  1-2µM entinostat (MS-275, abbreviated as
MS). Cell death and the loss of δΨM were quantified
by flow cytometry after 48-h treatment periods. (C)
CRC short-term cultures were incubated with 0,5-
10 µM MS and irinotecan for 48h. HROC24 cells were
treated with 2 µM Iri and HROC113/HHC6548 cells
with 3 µM Iri. All graphs in (C) show the average of 3
independent experiments  SEM; significances for this
figure are: * p<0.05; ** p<0.01; *** p<0.001 to MS-
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275; ° p<0.05; °° p<0.01; °°° p<0.001 to irinotecan
using two-tailed t-tests. HCT116wt and HCT116δp53
cells were exposed to 10 µM Iri  2 µM MS. Addi-
tionally, cells were 1h pretreated with 20 µM zVAD
alone and  Iri/MS. (D) The loss of δΨM and cell
death were quantified by flow cytometry after 48h.
Cellular senescence was analyzed by β-galactosidase
staining after 24h (E) and 48h (F). Red arrows indi-
cate β-galactosidase-positive cells. (G) Representative
images of a BALB/c cell transformation assay after
72h of treatment with 10 µM Iri + 2 µM MS. MCA/
TPA-transformed cell foci are Giemsa stained and
appear in blue. Quantification of the number of malig-
nancy-associated type-III foci/well is shown. All fig-
ures/graphs are representative/show the mean value of
3 independent experiments  SEM; significances for
these figure are: * p<0.05; ** p<0.01; *** p<0.001
using two-tailed t-tests. (H,I) 6- to 8-week-old NMRI-
Foxn1nu mice were treated with 20mg/kg Iri and
2,5mg/kg MS for 16 days. (H) Changes in their body
weights were monitored daily. (I) The weight of whole
livers was documented after 16 days of therapy and
are shown as mean values  SEM.
Fig. S2. Irinotecan plus entinostat induces DNA dam-
age in p53 wild-type CRC cells. HCT116wt cells were
exposed to 10 µM irinotecan (Iri)  2 µM entinostat/
MS-275 (MS) for 24h or irradiated with 2Gy for 2h
before fixation. The expression and localization of
53BP1 (A) or RAD51 (B) together with γH2AX (red)
was analyzed by fluorescence microscopy. DAPI was
used as nuclear stain. Single channels as well as
merged pictures are shown. Pictures are representative
for 3 individual experiments. (C) HCT116wt and
HROC24 cells were exposed to 5 µM Iri  2 µM MS
for 24h. Levels of indicated proteins cells were ana-
lyzed by immunoblot; HSP90 served as loading con-
trol. Immunoblots are representative for 2 independent
experiments.
Fig. S3. Irinotecan plus entinostat induces DNA dam-
age in p53 null CRC cells. HCT116δp53 cells were
exposed to 10 µM irinotecan (Iri)  2 µM entinostat/
MS-275 (MS) for 24h or irradiated with 2Gy for 2h
before fixation. The expression and localization of
53BP1 (A) or RAD51 (B) together with γH2AX (red)
was analyzed by fluorescence microscopy. DAPI was
used as nuclear stain. Single channels as well as
merged pictures are shown. Pictures are representative
for 3 individual experiments.
Fig. S4. Irinotecan plus entinostat increases the C-ter-
minal acetylation of p53 in CRC cells. HCT116wt and
HCT116δp53 cells were exposed to 10 µM irinotecan
(Iri)  2 µM entinostat/MS-275 (MS) for 24h. (A)
Protein expression levels of indicated proteins and
acetylation of p53 were analyzed by immunoblot and
quantified using LiCor Odyssey Software; the ratios of
acetylated over total p53 were calculated (B). HSP90
served as loading control. RKO (C), HROC24, and
HHC6548 (D) cells were exposed to 5 µM Iri  2 µM
MS. Protein expression levels of indicated proteins and
acetylation of p53 were analyzed by immunoblot after
24-h treatment periods. HSP90 and β-actin served as
loading control. HCT116wt and HCT116δp53 cells were
exposed to 10 µM Iri  2 µM MS. (E) Levels of indi-
cated proteins were analyzed by immunoblot after 48h;
α-tubulin served as loading control. HCT116wt and
HROC24 cells were exposed to 5 µM Iri  500nM
navitoclax (ABT-263, abbreviated as ABT). (F) The
percentage of annexin-V-positive (i.e., apoptotic)
HROC24 cells was quantified by flow cytometry after
48h. (G) Levels of indicated proteins were analyzed by
immunoblot after 24h; HSP90 served as loading con-
trol. (A-B) show 1 representative experiment each (C-
G) are representative for/show the mean value of 2
individual experiments.
Fig. S5. C-terminally acetylated p53 locates at mito-
chondria after treatment with irinotecan plus entinos-
tat. HCT116wt and HCT116δp53 cells were exposed to
10 µM irinotecan (Iri)  2 µM entinostat/MS-275
(MS) for 24h. (A) Mitochondrial morphologies in
HCT116δp53 cells were analyzed by TEM. Represen-
tative mitochondria are shown enlarged in the top left
corner of each panel. Black arrows indicate damaged
mitochondria. (B) Localization of immune-gold-labeled
p53 was analyzed by TEM on freeze-fractures from
HCT116wt cells. Gold particles are indicated by black
arrows and shown enlarged in the bottom left corner
of each panel. RKO (C-E) and HROC113 (F-H) cells
were exposed to 10 µM Iri  2 µM MS for 24h. Cell
lysates were fractionated into mitochondria and cyto-
sol. The expression of indicated proteins, localization,
and modification of p53 in RKO (C) and HROC113
cells (F) was analyzed by immunoblot. ATP5A served
as mitochondrial protein loading. Quantification of
corresponding p53 PTMs was done by ImageJ; the
ratios of mitochondrial (mt)-pS15- and mt-acK382-
over total p53 in RKO (D) and HRCO113 cells (G),
were calculated. Quantification of mitochondrial total
p53 level is shown in (E) for RKO and in (H) for
HROC113 cells. HCT116wt and HCT116δp53 cells were
exposed to 10 µM Iri  2 µM MS for 24h. (I) Cell
lysates were fractionated into mitochondria and cyto-
sol. The expression of indicated proteins was analyzed
by immunoblot. HSP90 and TOM40 served as protein
loading control within individual compartments. Tetra-
cyclin-induced H1299 TO p53wt or H1299 TO
p53K120R cells were exposed to 10 µM Iri  2 µM
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MS. (J-K) Cell lysates were fractionated into mito-
chondria and cytosol after 24h. The expression, local-
ization, and acetylation of p53 was analyzed by
Immunoblot. HSP90 and TOM40 served as protein
loading control within individual compartments. (L)
The loss of δΨM was quantified by flow cytometry
after 48h. (A-L) are representative for/show the mean
value of 2 individual experiments  SEM; # indicate
long exposures of corresponding proteins for immuno-
blots.
Fig. S6. Differential gene expression of HATs and
HDACs in human cancer samples. Gene expression of
The Cancer Genome Atlas (TCGA) datasets was ana-
lyzed for indicated genes using Gene DE module in
the Timer web platform. Differences in gene expression
level are depicted as log2-fold change. Colon adeno-
carcinomas (COAD) and rectum adenocarcinomas
(READ) are highlighted. Significances for this figure
are: * p<0.05; ** p<0.01; *** p<0.001.
Fig. S7. Differential gene expression of BCL2 proteins
in human cancer samples. Gene expression of The
Cancer Genome Atlas (TCGA) datasets was analyzed
for indicated genes using Gene DE module in the
Timer web platform. Differences in gene expression
level are depicted as log2-fold change. Colon adeno-
carcinomas (COAD) and rectum adenocarcinomas
(READ) are highlighted. Significances for this figure
are: * p<0.05; ** p<0.01; *** p<0.001.
Fig. S8. C-terminally acetylated p53 is necessary to
induce apoptosis by irinotecan plus entinostat. RKO
(A), HROC24, and HHC6548 (B) cells were exposed
to 5 µM irinotecan (Iri) + 2 µM MS-275 (MS) 
200nM CPI-1612 (CPI). Levels of indicated proteins
and acetylation of p53 were analyzed by immunoblot
after 24h. HSP90 served as loading control. RKO (C-
D) and HROC113 (E-F) cells were exposed to 10 µM
Iri + 2 µM MS  200nM CPI. Cell lysates were frac-
tionated into mitochondria and cytosol after 24h. The
expression of indicated proteins, localization, and
acetylation of p53 in RKO (C) and HROC113 cells
(E) was analyzed by immunoblot. ATP5A served as
mitochondrial protein loading. Quantification of p53
acetylation was done by ImageJ; the ratios of mito-
chondrial mt-acK382- over total p53 in RKO (D) and
HRCO113 cells (F) were calculated and the expression
of total p53 is shown correspondingly. (G-H)
HROC24 cells were exposed to 10 µM Iri  2 µM MS
 200nM CPI. Cell lysates were fractionated into
mitochondria and cytosol after 24h. The expression of
indicated proteins, localization, and acetylation of p53
was analyzed by immunoblot (G). ATP5A served as
mitochondrial protein loading. Quantification of p53
acetylation was done by ImageJ; the ratios of
mitochondrial mt-acK382- over total p53 (H) were cal-
culated and the expression of mitochondrial total p53
is shown correspondingly. (I) HROC24 cells were
exposed to 5 µM Iri + 2 µM MS  200nM CPI for
48h. The percentage of apoptotic Annexin-V-positive
was quantified by flow cytometry afterward. (J)
HCT116wt cells were exposed to 5 µM Iri  500nM
ABT-263 (ABT)  200nM CPI for 48h. The percent-
age of apoptotic Annexin-V-positive was quantified by
flow cytometry afterward. (K) RKO cells were exposed
to 5 µM Iri + 500nM ABT  200nM CPI for 72h.
The percentage of apoptotic Annexin-V-positive was
quantified by flow cytometry afterward. (L)
HCT116δp53 were transient transfected with empty
vector (δp53 - EV) for control, wild-type p53 (δp53 -
p53wt), or acetylation incompetent p536KR (δp53 -
p536KR) and were exposed to 10 µM Iri + 2 µM MS
for 24h. Cell lysates were fractionated into mitochon-
dria and cytosol. The expression of indicated proteins,
localization, and acetylation of p53 was analyzed by
immunoblot. HSP90 and TOM40 served as protein
loading control within individual compartments. (M)
Stable transfected HCT116δp53 expressing either
empty vector (δp53 - EV) for control or acetylation
incompetent p536KR (δp53 - p536KR) were exposed
to 10 µM Iri  2 µM MS  200nM CPI. Levels of
indicated proteins were analyzed by immunoblot after
48h. α-tubulin served as loading control. (I-J) show the
mean value of 3 independent experiments  SEM. (A-
H) and (K-M) all immunoblots and graphs are repre-
sentative for/show the mean value of 2 independent
experiments  SEM. Significances for this figure are: *
p<0.05; ** p<0.01; *** p<0.001 using two-tailed t-
tests. # indicate long exposures of corresponding pro-
teins for immunoblots.
Fig. S9. C-terminally acetylated p53 interacts with
BAK to promote apoptosis. HROC24 cells were
exposed to 5 µM irinotecan (Iri)  2 µM entinostat/
MS-275 (MS)  200nM CPI-1612 (CPI). BCL-XL (A)
and BAK (B) were immunoprecipitated from cell
lysates and expression levels of indicated proteins and
acetylation of p53 were analyzed by immunoblot after-
ward. RKO cells were exposed to 10 µM Iri  2 µM
MS  200nM CPI. BCL-XL (C) and BAK (D) were
immunoprecipitated from cell lysates and expression
levels of indicated proteins and acetylation of p53 were
analyzed by immunoblot afterward. All immunoblots
and graphs are representative of 2 independent experi-
ments. # indicate long exposures of corresponding pro-
teins for immunoblots.
Table S1. Synergistic interaction of irinotecan plus
entinostat combinations in CRC cells. HCT116wt and
HCT116δp53 cells were exposed to 1-20 µM irinotecan
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(Iri)  1-2 µM entinostat (MS-275, abbreviated as
MS). Cell death and the loss of ΨM were quantified by
flow cytometry after 48h treatment periods. CI-values
were calculated with CalcuSyn from these dose-re-
sponse curves (see Figures S1A-B).
Table S2. Differential gene expression of HATs and
HDACs in human cancer cell lines. Gene expression
data of indicated genes in the NCI-60 cell line panel
were exported using the CellMiner web tool. Changes
of transcript intensities are depicted as z-scores. CRC
cell lines (CO) are highlighted.
Table S3. Mutations of HAT and HDAC genes in
human cancer cell lines. Mutations of indicated genes in
the NCI-60 cell line panel were exported using the Cell-
Miner web tool. The number of mutations as absolute
numbers. CRC cell lines (CO) are highlighted.
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